Some studies show that MRI may be better at identifying multifocal and multicentric disease, particularly for some DCIS and lobular cancers.
MRI is useful in patients with axillary lymphadenopathy due to occult disease. It is also useful in detecting cancer or early changes in the contralateral breast.
MRI is more sensitive than ultrasound or CT scan to assess the lymph node involvement in the mediastinum and axilla- thus helping staging.
Silicone implant rupture can have detection rates of 99% with MRI. It is a challenge to detect early cancer in an augmented breast, particularly with rupture, because carcinomatous change may be misinterpreted as silicone mastopathy or nodularity, skin retraction or nipple inversion.
MRI allows objective assessment of response to chemotherapy and assessment of reduction or residual tumour size and restaging of the axilla.
MRI is now an established tool in our armament for diagnosis and management of breast cancer.
Its limitations of high sensitivity and cost mean in Australia we only use it for select cases.
The judicious use of MRI leads to better management of screening high risk patients, better outcomes in the work up of disease and reduced morbidity and mortality to provide the patient with the best surgical and medical option the first time.